Novocure's TTFields show positive effect in mid-stage mesothelioma study [Seeking Alpha]
NovoCure Limited - Ordinary Shares (NVCR)
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
novocure.com/investor-relations
Company Research
Source: Seeking Alpha
Novocure's TTFields show positive effect in mid-stage mesothelioma studyTopline results from a Phase 2 pilot study, STELLAR, assessing Novocure's (NASDAQ:NVCR) Tumor Treating Fields (TTFields) plus chemo in patients with mesothelioma showed a positive effect compared to chemo alone (historial control).STELLAR is an 80-subject, single-arm, open-label trial evaluating TTFields plus standard-of-care chemo pemetrexed combined with either cisplatin or carboplatin in patients with unresectable previously untreated pleural mesothelioma.Treatment with TTFields produced clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS).Preliminary data on 42 subjects with an average of 11.5 months of follow-up showed a one-year survival rate of 80% compared to 50% for historical control. Median PFS was 7.3 months versus 5.7 months for historial control. Median OS had not been reached.Detailed results will be submitted for presentation at an upcoming medical confere
Show less
Read more
Impact Snapshot
Event Time:
NVCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
News
- NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $21.00 price target on the stock.MarketBeat
- NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at HC Wainwright from $22.00 to $24.00. They now have a "neutral" rating on the stock.MarketBeat
- METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerBusiness Wire
- NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at JPMorgan Chase & Co. from $15.00 to $17.00. They now have a "neutral" rating on the stock.MarketBeat
- Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect? [Yahoo! Finance]Yahoo! Finance
NVCR
Earnings
- 2/22/24 - Beat
NVCR
Sec Filings
- 3/27/24 - Form 8-K
- 3/5/24 - Form 4
- 3/5/24 - Form 4
- NVCR's page on the SEC website